prikaz prve stranice dokumenta Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).
  Download
PDF 2.78 MB
Scientific paper - Original scientific paper
Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).
Translational Lung Cancer Research, 8 (2019), 6; 1000-1015. https://doi.org/10.21037/tlcr.2019.12.08
Šutić, Maja; Motzek, Antje; Bubanović, Gordana; Linke, Matthias; Sabol, Ivan; Vugrek, Oliver; Ozretić, Petar; Brčić, Luka; Seiwerth, Sven; Debeljak, Željko; Jakovčević, Antonija; Janevski, Zoran; Stančić-Rokotov, Dinko; Vukić-Dugac, Andrea; Jakopović, Marko; Samaržija, Miroslav; Zechner, Ulrich; Knežević, Jelena More authors...

Cite this document

Šutić, M., Motzek, A., Bubanović, G., Linke, M., Sabol, I., Vugrek, O. ... Knežević, J. (2019). Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).. Translational Lung Cancer Research, 8. (6), 1000-1015. doi: 10.21037/tlcr.2019.12.08

Šutić, Maja, et al. "Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).." Translational Lung Cancer Research, vol. 8, no. 6, 2019, pp. 1000-1015. https://doi.org/10.21037/tlcr.2019.12.08

Šutić, Maja, Antje Motzek, Gordana Bubanović, Matthias Linke, Ivan Sabol, Oliver Vugrek, Petar Ozretić, et al. "Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).." Translational Lung Cancer Research 8, no. 6 (2019): 1000-1015. https://doi.org/10.21037/tlcr.2019.12.08

Šutić, M., et al. (2019) 'Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).', Translational Lung Cancer Research, 8(6), pp. 1000-1015. doi: 10.21037/tlcr.2019.12.08

Šutić M, Motzek A, Bubanović G, Linke M, Sabol I, Vugrek O, and sur.. Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).. Translational Lung Cancer Research [Internet]. 2019 [cited 2024 November 16];8(6):1000-1015. doi: 10.21037/tlcr.2019.12.08

M. Šutić, et al., "Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).", Translational Lung Cancer Research, vol. 8, no. 6, pp. 1000-1015, 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:239:910974. [Accessed: 16 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Promoter Methylation Status of ASC/TMS1/PYCARD is Associated with Decreased Overall Survival and TNM Status in Patients with Early Stage Non-small Cell Lung Cancer (NSCLC).
AuthorMaja Šutić
MBZ: 362344
AuthorAntje Motzek
AuthorGordana Bubanović
MBZ: 319765
AuthorMatthias Linke
AuthorIvan Sabol
MBZ: 268915
AuthorOliver Vugrek
MBZ: 232935
AuthorPetar Ozretić
MBZ: 295840
AuthorLuka Brčić
MBZ: 272221
AuthorSven Seiwerth
MBZ: 149676
AuthorŽeljko Debeljak
MBZ: 296571
AuthorAntonija Jakovčević
AuthorZoran Janevski
AuthorDinko Stančić-Rokotov
MBZ: 216873
AuthorAndrea Vukić-Dugac
MBZ: 353752
AuthorMarko Jakopović
MBZ: 278365
AuthorMiroslav Samaržija
MBZ: 146943
AuthorUlrich Zechner
AuthorJelena Knežević
MBZ: 242431
Author's institutionRuđer Bošković Institute
Author's institution(Clinical hospital center Osijek)
Author's institutionJosip Juraj Strossmayer University of Osijek
Faculty of Medicine Osijek
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Oncology
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Immunology
Abstract (english)
BACKGROUND: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the activation of the innate immune response and apoptosis pathways. METHODS: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Methylation of bisulphite converted DNA was quantified by pyrosequencing in fresh frozen malignant tissues and adjacent non-malignant tissues. Associations between methylation and lung function, tumor grade and overall survival were evaluated using receiver-operating characteristics (ROC) analysis and statistical tests of hypothesis. RESULTS: Methylation level of tested genes is generally low but significantly decreased in tumor tissues (ASC/TMS1/PYCARD, P<0.0001; MyD88, P<0.0002), which correlates with increased protein expression. Three CpG sites were identified as promising diagnostic marker candidates; CpG11 (-63 position) in ASC/TMS1/PYCARD and CpG1 (-253 position) and 2 (-265 position) in MyD88. The association study showed that the methylation status of the ASC/TMS1 CpG4 site (-34 position) in malignant and non-malignant tissues is associated with the overall survival (P=0.019) and the methylation status of CpG8 site (-92 position) is associated with TNM-stage (P=0.011). CONCLUSIONS: The methylation status of the ASC/TMS1/PYCARD and MyD88 promoters are promising prognostic biomarker candidates. However, presented results should be considered as a preliminary and should be confirmed on the larger number of the samples.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleTranslational Lung Cancer Research
Numberingvol. 8, no. 6, pp. 1000-1015
p-ISSN2218-6751
e-ISSN2226-4477
DOIhttps://doi.org/10.21037/tlcr.2019.12.08
URN:NBNurn:nbn:hr:239:910974
Publication2019
Document URLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6976376/
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2020-04-29 09:39:20